As we will discuss later, this further justified the development of synthetic GLP-1/glucagon co-agonists as promising weight loss therapeutics, particularly in the context of avoiding unwanted hyperglycaemia in obesity-associated type 2 diabetes
This can cause irregular menstrual cycles or temporarily absent periods, disrupted ovulation timing where you might ovulate earlier or later than expected, changes in estrogen, progesterone, and other reproductive hormones, and temporary changes in cervical mucus quality
GLP-1 agonists are still a go-to for many due to their strong safety record and expanding availability, including oral options
We've seen brilliant research designs undermined by simple, avoidable errors in handling
Insulin therapy may involve multiple injections, blood glucose monitoring, and record-keeping